Release date: 2017-06-27 For blood cancers such as acute myeloid leukemia (AML), most methods attack the cancer cells themselves. Now, Pfizer scientists have found a way to get cancer cells out of hiding and make them more vulnerable. Source: WuXi PharmaTech
1. What is SARMS? Is SARMS a drug? 99% Powder Agmatine Sulfate,Powder Agmatine Sulfate,Agmatine Sulfate Powder Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropic.com
AML is a hematological malignancy caused by abnormal proliferation of myeloid hematopoietic cells. The rapid proliferation of these cells affects the production of normal hematopoietic cells. As the most common acute leukemia in adults, the incidence of AML increases with the age of the person, but the cure rate decreases. According to the data in The New England Journal of Medicine, the cure rate is about 35%-40% in people under 60 years of age. However, once the onset age is over 60 years old, the cure rate is reduced to 5%-15%, and the average survival rate of the elderly who cannot afford strong chemotherapy is 5-10 months. Therefore, these patients are in urgent need of new treatments. 
In malignant tumors, the highly expressed chemokine receptor CXCR4, upon binding to its ligand CXCL12, triggers an intracellular signaling pathway that controls the transfer of cells into tissues such as bone marrow. In blood cancer, the protective mechanism of CXCR4-driven bone marrow on malignant cells is the key to the development of the disease and making it difficult to treat. Based on this pathway, Pfizer developed a humanized CXCR4 antibody called PF-06747143, which is expected to bind CXCR4 and inhibit CXCL12-mediated signaling and cell migration. Therefore, this new drug is expected to allow AML cells to leave the bone marrow and enter the bloodstream, which is attacked by other effective therapies. In addition, PF-06747143 is also expected to induce tumor cell death through its Fc constant region-mediated effector function. 
Pfizer's work on the new drug PF-06747143 (Source: ScienceDaily)
These ideas were validated in preclinical studies. Dr. Flavia Pernasetti of Pfizer's Oncology Research and Development Department led a research team. They found that in the AML mouse model, the drug kills up to 96% of cancer cells when used alone, and when combined with the chemotherapy drugs daunorubicin and cytarabine When used, it kills more than 99% of cancer cells. More interestingly, this new drug may also be suitable for blood cancers such as non-Hodgkin's lymphoma and multiple myeloma. The new discovery was also published in Blood Advances.
Dr. Pernasetti said: "One of the main limitations we have seen in the treatment of blood cancer is that there is no way to remove cancer cells from the bone marrow. Because bone marrow provides a good environment for cancer cells to grow, it is effective to remove these cancer cells from the bone marrow. An important step in the treatment of these malignancies. Our approach not only has the potential to drive cancer cells out of the bone marrow, but also directly attack cancer cells."
Dr. Pernasetti said her team is looking forward to seeing the performance of PF-06747143 in Phase 1 clinical trials. The trial is recruiting AML patients in hospitals in Arizona, Illinois, and North Carolina and evaluating them as separate and combination therapies. We are expecting a successful trial of this new drug and bringing new treatments to patients.
SARMS is a selectively targeted androgen receptor modulator.
By regulating the receptivity and availability of androgens to muscle cells, which correspond to Steroids. Steroids are exogenous androgens, while SARMS regulates the absorption and use of androgens in muscles. Both exogenous and endogenous androgens can be regulated. So the results of steroid +SARMS can be imagined!
SARMS is not strictly a drug; it is a substance that sits somewhere between a supplement and a drug.
2. What are the characteristics and advantages of SARMS?
SARMS, a selective androgen receptor modulator, is considered as a bridging compound in bodybuilding that produces similar results to steroids, but without the same side effects. All SARMS do not suppress viscera, have no hepatotoxicity, and do not transfer to females.
3. Introduction of SARMS common categories?
SARMS series of quality products :S4, YK-11, GW-501516, LGD-4033, MK2866, MK-677, RAD-140,LGD-3303, SR9009
Mk-2866: MK2866- Selectively performs anabolic activity on certain ARs, which is very helpful for maintaining and increasing lean meat quality and resilience.
Lgd-4033 - A powerful non-steroidal bodybuilding supplement used to enhance muscle mass and reduce body fat
Ostarine (MK-2866) - Selective anabolic activity, well suited for maintenance